Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
Author:
Open Access
- 1 June 2013
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 7, 519-27
Abstract
Peer reviewed article authored by (Cowey CL). Read article or submit your manuscript for publishing.Keywords
This publication has 25 references indexed in Scilit:
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III TrialJournal of Clinical Oncology, 2013
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- VEGF as a Key Mediator of Angiogenesis in CancerOncology, 2005
- Role ofVHLGene Mutation in Human CancerJournal of Clinical Oncology, 2004
- Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.2001
- Cytokine therapy for metastatic renal cell carcinoma.2001
- Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 1999
- Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.1994
- Mutations of the VHL tumour suppressor gene in renal carcinomaNature Genetics, 1994